WaveMan
WaveMan · Company
ELOX · Eloxx Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ELOX Eloxx Pharmaceuticals (ELOX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001035354
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
22
13F, latest reported quarter

Eloxx Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Eloxx Pharmaceuticals, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Geffken Daniel E.
INTERIM CFO
BUY
2021-12-01 SECtraded 2021-11-29
50,000
$36.0K
+19.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 50,000 shares held after it.
  • No other insider bought within 30 days.
  • 22 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: INTERIM CFO Geffken Daniel E. bought about $36.0K of ELOX on Nov 29, 2021, the largest insider purchase at the company on our record; 22 funds added in the latest 13F quarter.
1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
22 funds bought in last quarter
below 67% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
4.4% of the float short (float per yahoo 2026-10-27) · 1.8 days to cover · settled 2026-10-15
below 72% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ELOX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+19.6%12M
-1%+30%+60%+91%2026-062026-072026-072026-082026-092026-102026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ELOX: institutional holders (13F)

13F holdings, latest reported quarter
Stonepine Capital Management, LLC
844,320 sh
$11.7M
Nantahala Capital Management, LLC
800,000 sh
$11.1M
EcoR1 Capital, LLC
400,000 sh
$5.6M
Aberdeen Group plc
400,000 sh
$5.6M
SAMSARA BIOCAPITAL, LLC
400,000 sh
$5.6M

Congress trades in ELOX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ELOX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ELOX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
VANGUARD EXTENDED MARKET INDEX FUND
$267.8K position · as of 2026-06-30
0.0%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND
$12.2K position · as of 2026-06-30
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$797.8K position · as of 2026-06-30
0.0%
VANGUARD BALANCED INDEX FUND
$14.4K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
3
Phase 2
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 22 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ELOX financials

Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
0.00x
long-term 2025-12-31 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
n/a
needs four quarters of operating cash flow
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
-$8.8M
market value at close 2026-10-26 on 2026-08-07 shares, plus long-term 2025-12-31 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$6.4M$0n/a
Operating income-$6.4M-$2.5M-$17.3M-$34.4M
Net income-$6.0M-$3.1M-$17.1M-$36.1M
EPS (diluted)-5.34-9.20-72.98-16.65
Operating cash flow-$6.3M-$4.7M-$14.3M-$31.8M
Cash$4.8M$111.0K$1.1M$19.2M
Long-term debt$0$0$1.6M$8.6M
SEC XBRL, fiscal years, as known on 2026-10-28

ELOX Stock Sonar score 4/7 axes

Find similar shapesCompare

ELOX ranks highest on financial health (99th percentile) and institutional and government (33rd), and lowest on growth (1st), among Pharma & Biotech peers.

Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 352
  • Cash flow to debtneeds four quarters of operating cash flow
Growth
0
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
33
Inputs
  • Funds adding, latest quarter22 · 33 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
30
Inputs
  • Short interest, % of float+5.8% · 55 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+47.0% · 5 pct, sector of 511
3 not measured: Profitability, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies